Literature DB >> 30266160

Cirrhosis and Portal Hypertension in the Pediatric Population.

Catherine A Chapin1, Lee M Bass2.   

Abstract

Cirrhosis is a complex process in which the architecture of the liver is replaced by structurally abnormal nodules due to cirrhosis. Cirrhosis frequently leads to the development of portal hypertension. In children, portal hypertension may be caused by a wide range of etiologies, including extrahepatic portal vein obstruction, biliary atresia, alpha 1 antitrypsin deficiency, and autoimmune hepatitis. Gastroesophageal varices and ascites are two of the complications of portal hypertension likely to cause morbidity and mortality. This review also discusses extrahepatic manifestations of portal hypertension and treatment options.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ascites; Biliary atresia; Children; Cirrhosis; Esophageal varices; Portal hypertension

Mesh:

Year:  2018        PMID: 30266160     DOI: 10.1016/j.cld.2018.06.007

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  11 in total

1.  The clinical value of color Doppler ultrasonography in measuring the hemodynamics of liver cirrhosis patients' portal and splenic veins.

Authors:  Ran Hui; Zhe Li; Zongjie Liu; Xiuping Liu; Heping Deng
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

2.  Diffusion tensor imaging of the spleen in prediction and grading of esophageal varices in cirrhotic children with portal hypertension.

Authors:  Ahmed Abdel Khalek Abdel Razek; Mona Mohamed Hafez; Walaa Mahmoud; Ahmed Ramadan Ismail; Khadiga M Ali; Tarek Elsayed Barakat
Journal:  Jpn J Radiol       Date:  2021-04-29       Impact factor: 2.374

3.  Clinically Evident Portal Hypertension: An Operational Research Definition for Future Investigations in the Pediatric Population.

Authors:  Lee M Bass; Benjamin L Shneider; Lisa Henn; Nathan P Goodrich; John C Magee
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-06       Impact factor: 2.839

4.  Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis.

Authors:  Lorena I Cifuentes; Daniela Gattini; Romina Torres-Robles; Juan Cristóbal Gana
Journal:  Cochrane Database Syst Rev       Date:  2021-01-26

5.  Beta-blockers versus placebo or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis.

Authors:  Lorena I Cifuentes; Daniela Gattini; Romina Torres-Robles; Juan Cristóbal Gana
Journal:  Cochrane Database Syst Rev       Date:  2021-01-26

6.  Sclerotherapy versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis.

Authors:  Daniela Gattini; Lorena I Cifuentes; Romina Torres-Robles; Juan Cristóbal Gana
Journal:  Cochrane Database Syst Rev       Date:  2020-01-10

7.  Band ligation versus sclerotherapy for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis.

Authors:  Juan Cristóbal Gana; Lorena I Cifuentes; Daniela Gattini; Romina Torres-Robles
Journal:  Cochrane Database Syst Rev       Date:  2020-11-06

8.  Sclerotherapy versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis.

Authors:  Daniela Gattini; Lorena I Cifuentes; Romina Torres-Robles; Juan Cristóbal Gana
Journal:  Cochrane Database Syst Rev       Date:  2020-03-05

9.  Outcomes following liver transplantation in young infants: Data from the SPLIT registry.

Authors:  Ajay K Jain; Ravinder Anand; Stacee Lerret; George Yanni; Jia-Yuh Chen; Saeed Mohammad; Majella Doyle; Greg Telega; Simon Horslen
Journal:  Am J Transplant       Date:  2020-09-05       Impact factor: 8.086

10.  Differential hepatic features presenting in Wilson disease-associated cirrhosis and hepatitis B-associated cirrhosis.

Authors:  Hao-Jie Zhong; Huan-Huan Sun; Lan-Feng Xue; Eileen M McGowan; Yu Chen
Journal:  World J Gastroenterol       Date:  2019-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.